OVID Archives - BioTuesdays

Developments

Ovid Therapeutics’ OV101 fails Phase 3 Angelman syndrome trial

Ovid Therapeutics (NASDAQ: OVID) reported that its Phase 3 NEPTUNE trial evaluating OV101 for the treatment of Angelman syndrome failed to meet its primary endpoint. Angelman syndrome is a rare genetic disorder that...

December 1, 2020

Developments

Ovid Therapeutics soticlestat meets primary endpoint in Phase 2 epilepsy trial

Ovid Therapeutics (NASDAQ:OVID) reported positive topline results from its Phase 2 study evaluating soticlestat in children with Dravet syndrome or Lennox-Gastaut syndrome, two highly refractory epilepsy syndromes...

August 25, 2020

Developments

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Ovid Therapeutics’ (NASDAQ:OVID) OV101 received FDA rare pediatric disease designation for the treatment of Angelman syndrome. Angelman syndrome is a rare genetic disorder that affects the brain’s ability to correctly...

June 19, 2020

Developments

Ovid Therapeutics reports positive topline results from Phase 2 Fragile X syndrome study

Ovid Therapeutics (NASDAQ:OVID) reported positive topline results from its Phase 2 trial of OV101 in males with Fragile X syndrome. A total of 23 participants were randomized to receive either 5 mg of OV101 either...

May 7, 2020

Developments

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Ovid Therapeutics (NASDAQ:OVID) reported positive initial data from its Phase 2 study of soticlestat, a cholesterol 24-hydroxylase inhibitor, in patients with rare developmental and epileptic encephalopathies (DEE). ...

September 24, 2019

Markets

Ladenburg starts Ovid Therapeutics at buy; PT $27

Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA...

April 20, 2018

Tag - OVID

Ovid Therapeutics’ OV101 fails Phase 3 Angelman syndrome trial

Ovid Therapeutics soticlestat meets primary endpoint in Phase 2 epilepsy trial

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Ovid Therapeutics reports positive topline results from Phase 2 Fragile X syndrome study

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Ladenburg starts Ovid Therapeutics at buy; PT $27

General

More